Notable research news last week included US biopharma Avidity Biosciences announcing a positive update on its muscular ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started ...

Fintel reports that on June 11, 2025, Raymond James initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Strong ...

Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and ...

Worldwide Healthcare Trust PLC - Annual Financial Report PR Newswire LONDON, United Kingdom, June 11 10 June 2025Worldwide Healthcare Trust PLC(the "Company") Annual Financial ...

Detailed price information for Avidity Biosciences Inc (RNA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Avidity Biosciences Inc (RNA-Q) from The Globe and Mail including charting and trades.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.42, along with a high estimate of $75.00 and a low estimate of $54.00. Surpassing the ...